Bridging Therapy: Transitioning Between Blood Thinners Safely

Switching between blood thinners isn’t just about swapping one pill for another. When a patient on long-term anticoagulation needs surgery, a dental procedure, or any intervention that increases bleeding risk, stopping their medication creates a dangerous window - the exact moment when clots can form. That’s where bridging therapy comes in. But here’s the twist: for most people, bridging isn’t needed anymore. In fact, doing it might be more harmful than helpful.

What Is Bridging Therapy - And Why It Used to Be Routine

Bridging therapy means using a short-acting injectable blood thinner - usually low molecular weight heparin (LMWH) like enoxaparin - to cover the gap when a patient stops their long-term anticoagulant. This was once standard practice. If you were on warfarin and needed a knee replacement, your doctor would stop your warfarin a week before surgery, start you on daily injections, and then restart warfarin after the procedure. The logic was simple: don’t leave you unprotected.

But that logic was built on fear, not data. Back in the 2000s, doctors assumed that stopping warfarin - even for a few days - meant your risk of stroke or clotting shot up. So they reached for heparin injections to fill the gap. By 2010, nearly half of all patients on warfarin undergoing surgery got bridged.

Then came the BRIDGE trial in 2015. Researchers randomly assigned over 2,000 patients with atrial fibrillation who needed temporary interruption of warfarin to either receive LMWH bridging or no bridging. The results were shocking. Bridging didn’t lower the risk of stroke or clots. But it doubled the chance of major bleeding. 2.3% of bridged patients had serious bleeding. Only 1% of those who didn’t get bridged did.

That study changed everything.

When Bridging Is Still Necessary - And When It’s Not

Today, bridging isn’t a default. It’s a last resort. The American Heart Association, American College of Cardiology, and European Heart Rhythm Association now agree: only a tiny group of patients needs it.

You likely need bridging if you have:

• A mechanical heart valve in the mitral position (not just any valve - specifically the mitral one)
• A recent blood clot in the lungs or legs (venous thromboembolism) within the last 3 months

That’s it. If you have atrial fibrillation with a CHA₂DS₂-VASc score of 4 or higher - even if you’ve had a stroke before - you still probably don’t need bridging. Studies show your risk of stroke during a short break is so low that the bleeding risk from injections outweighs it.

You do NOT need bridging if:

• You’re on a direct oral anticoagulant (DOAC) like apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban (Savaysa)
• You have atrial fibrillation without a recent clot or mechanical valve
• You’re on warfarin but your CHA₂DS₂-VASc score is below 5

DOACs are the game-changer here. Unlike warfarin, which takes days to clear from your system and requires constant INR monitoring, DOACs work fast and leave fast. Their half-lives range from 5 to 17 hours. That means if you stop your pill on Monday morning, by Wednesday evening, it’s mostly gone - and you’re not at high risk. No injections needed.

How Bridging Works - Step by Step (For the Few Who Need It)

If you’re one of the 10-15% who still need bridging, timing is everything. Mess it up, and you’re at risk for either a clot or a bleed.

For warfarin patients needing bridging:

1. Stop warfarin 5-6 days before surgery. This lets your INR drop below 2.0. If your INR is still high at day 5, you may need to wait longer.
2. Start LMWH 3 days before surgery. Most use enoxaparin 1 mg/kg once daily (or 0.5 mg/kg twice daily for higher-risk cases).
3. Stop LMWH 24 hours before surgery. If it’s a high-bleeding-risk procedure like brain or spinal surgery, some doctors wait 36-48 hours.
4. Restart warfarin 12-24 hours after surgery. Start at 15-20% higher than your previous daily dose. Your body may need more to get back into range.
5. Check INR in 3-4 days. Don’t wait a week. You need to know if you’re back in the therapeutic range (usually 2.0-3.0 for most patients).

Timing for other agents:

• Fondaparinux: Stop 36-48 hours before surgery
• Unfractionated heparin (IV): Stop 4-6 hours before surgery

Important note: Always check kidney function before starting LMWH. If your creatinine clearance is below 30 mL/min, you’re at higher risk of bleeding. Dose reductions or alternatives may be needed.

Why DOACs Made Bridging Obsolete for Most

In 2023, 75% of new anticoagulant prescriptions in the U.S. were for DOACs. That’s not an accident. They’re easier. Safer. More predictable.

Here’s how to handle DOACs around surgery:

• Apixaban (Eliquis): Hold for 2 days before low-bleeding-risk procedures. Hold for 3-4 days before high-risk ones. Restart 6-24 hours after surgery if bleeding is controlled.
• Rivaroxaban (Xarelto): Hold 2 days before low-risk, 3 days before high-risk. Restart same day or next day post-op.
• Dabigatran (Pradaxa): Hold 2 days before low-risk, 3-4 days before high-risk. If kidney function is poor, hold longer.

No bridging. No injections. No INR checks. Just timing. This is why DOACs are now first-line for most patients with atrial fibrillation.

The Hidden Dangers of Bridging

Even when done perfectly, bridging has downsides:

• Bleeding risk: The BRIDGE trial showed a 2.3% major bleeding rate with bridging vs. 1.0% without. That’s more than double.
• Logistical burden: Daily injections are painful. Many patients skip doses - studies show 15-20% non-adherence. Missed doses mean clots. Extra doses mean bleeding.
• Cost: A 7-day course of LMWH in the U.S. costs $300-$500. That’s out-of-pocket for many. In the UK, NHS supply is limited, and delays can disrupt surgery schedules.
• Confusion: When do you restart warfarin? What dose? When to check INR? Patients often get conflicting advice from surgeons, pharmacists, and primary doctors.

And here’s the kicker: some studies show that keeping warfarin going - even during minor procedures - causes less bleeding than stopping it and bridging. One 2016 study found patients who kept warfarin at therapeutic levels during dental work had fewer bleeding complications than those who stopped and bridged.

What Doctors Get Wrong - And How to Avoid It

Many clinicians still default to bridging out of habit. Or because a surgeon says, “We need zero anticoagulation.” But that’s outdated thinking.

Key mistakes:

• Assuming all atrial fibrillation patients need bridging
• Starting LMWH too early (before INR is low enough)
• Restarting warfarin too late after surgery
• Not checking kidney function before giving LMWH
• Using bridging for DOAC patients - which is unnecessary and dangerous

What to do instead:

• Use the CHA₂DS₂-VASc score to assess stroke risk - not just “I have AFib.”
• Use the HAS-BLED score to assess bleeding risk - don’t ignore it.
• Ask: “Is this patient truly at high thrombotic risk?” If not, skip bridging.
• Coordinate between surgeon, primary care, and pharmacy. A single plan prevents chaos.
• For DOACs: follow the half-life. No more guessing.

What Patients Should Ask Before Surgery

If you’re on a blood thinner and have a procedure coming up, don’t wait for your doctor to bring it up. Ask these questions:

• “Am I on warfarin or a DOAC?”
• “Do I really need bridging, or is that just old practice?”
• “What’s my CHA₂DS₂-VASc score? Am I truly high-risk for stroke?”
• “If I stop my medicine, what’s the risk of a clot?”
• “If I don’t get bridging, how will you manage bleeding risk during surgery?”
• “When exactly do I stop and restart? Can I get this in writing?”

Most patients don’t realize they have a say. But your safety depends on asking.

The Future: Less Bridging, More Precision

The trend is clear: bridging therapy is shrinking. It’s no longer a standard. It’s a niche intervention for a very small group.

DOACs are replacing warfarin in 7 out of 10 new cases. As more patients switch, the need for bridging will drop even further. New guidelines in 2024 from the European Society of Cardiology are pushing for even stricter criteria - possibly limiting bridging to only mechanical mitral valves.

Meanwhile, research is exploring “step-up” approaches: instead of injecting heparin before surgery, give a low-dose injection just after - and only if bleeding is controlled. This could eliminate the dangerous gap entirely.

For now, the rule is simple: Don’t bridge unless you absolutely must. Most people don’t need it. And for those who do, precision matters more than tradition.

Final Takeaway

Bridging therapy isn’t dead - but it’s not the safety net it used to be. For most people on blood thinners, the best move is to avoid interruption altogether. If you’re on a DOAC, you’re already ahead. If you’re on warfarin, ask your doctor: “Is bridging really necessary for me?” The answer, more often than not, is no.